In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction

This publication has 26 references indexed in Scilit:

• Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids
  Clinical Cancer Research, 2004
• Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
  Breast Cancer Research, 2003
• Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens
  Journal of Clinical Oncology, 2002
• Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies
  Anti-Cancer Drugs, 2001
• Tumor-antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
  International Journal of Cancer, 1999
• Performance of calibration standards for antigen quantitation with flow cytometry
  Cytometry, 1998
• Towards an Immunotherapy for p185HER2 Overexpressing Tumors
  Published by Springer Nature ,1994
• Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
  Cancer Immunology, Immunotherapy, 1993
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
  Breast Cancer Research and Treatment, 1992
• Humanization of an anti-p185HER2 antibody for human cancer therapy.
  Proceedings of the National Academy of Sciences, 1992